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Abstract. External beam pituitary irradiation has been fre-
quently used in the treatment of growth hormone (GH)
secreting pituitary adenomas. Many studies have demon-
strated that serum GH declines rapidly and reliably follow-
ing treatment and early “cure” rates, based on a basal
serum GH below 10 lg/L were as high as 80%. The de~nition
of “cure” has become more stringent over time and retro-
spective studies have indicated that GH must be below 2.5
lg/L for acromegalics to achieve mortality rates comparable
to a normal population. Only 20% of irradiated patients will
achieve this goal by 10 yr. Even fewer will achieve a normal
serum insulin-like growth factor I (IGF-I) levels. Although
pituitary irradiation still has a role in the control of tumor
size, its importance as a treatment for normalizing serum
GH is being reevaluated.
Keywords. growth hormone, adenoma, anterior pituitary,
insulin-like growth factor I, neoplasia
Introduction
Acromegaly is a chronic disease that when inade-
quately treated results in signi~cant  morbidity  and
greatly increased mortality. Over the past 10–15 yr the
treatment options for this disease have increased.
Re~nements in transphenoidal pituitary adenomec-
tomy have occurred. However, despite advances in mi-
crosurgical techniques, surgery frequently does not re-
sult in cure. Long acting somatostatin analogs are
available but are expensive and not uniformly effec-
tive. In the past, patients who were not cured by sur-
gery underwent subsequent external beam irradiation
of the pituitary with the expectation that tumor
growth would be prevented, GH hypersecretion elimi-
nated and the patient “cured”. As will be discussed,
this treatment is effective in decreasing GH. However,
recent data suggest that pituitary irradiation in acro-
megaly infrequently results in a cure.
What De~nes “Cure” in Acromegaly
A major dif~culty in determining the ef~cacy of the
various treatments for acromegaly has been the de~ni-
tion of “cure” for the disease. Clayton recently outlined
criteria for the determination of an absolute biochemi-
cal cure [1]. These included (a) restoration of normal
secretory dynamics; (b) abolition of paradoxical GH
responses and (c) normalization of basal GH and IGF-I
to age- and gender-speci~c ranges. Not all of these
criteria have been equally addressed, and most studies
on the ef~cacy of pituitary irradiation have been lim-
ited to normalization of basal serum GH concentration
and to a lesser degree, abolition of paradoxical GH
responses.
Over the past 15 yr there has been an evolution re-
garding the de~nition of what is a normal, basal serum
GH concentration. For many years, reports on surgical
treatment used serum GH concentrations of less than 10
lg/L as criteria for effective therapy. Using this cut-off,
cure rates as high as 89% for microadenomas and 68%
for macroadenomas were reported [2]. Based on this
same cut-off, high  “cure” rates using bromocriptine
were also claimed [3]. As normal and abnormal GH se-
cretion was more thoroughly studied, it became appar-
ent that many, if not all of the patients with a random
serum GH concentration below 10 lg/L were not cured
and still had clinically active disease [3]. Accordingly,
more recent surgical series have used a cut-off for ran-
dom GH measurement of 5 lg/L as a de~nition of suc-
cessful outcome. Surgical “cure” rates with this more
stringent criterion were 70–83% for microadenomas
and 35–69% for macroadenomas [4,5]. However, as dis-
cussed below, a patient with a serum GH of 5 lg/L is
likely to still have active acromegaly. When the criteria
of cure are based on a basal GH of less than 2.5 lg/L, the
surgical cure rate dropped to 42% and 30% for micro-
and macroadenomas respectively [5].
It would be reasonable to de~ne “cure” as a post-
treatment mean serum GH concentration that was cer-
tain to return an  acromegalic patient’s mortality to
normal and to arrest the progression of GH-dependent
morbidity. This would be the case even if GH secretory
patterns were not identical to that of the normal popu-
lation. Since the disease is rare and the morbidities
studied take many years to develop, determining this
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cut-point is dif~cult. Retrospective analyses have sug-
gested that longevity in acromegalic patients corre-
lated with the last measured serum GH. The lower the
value, the better the chances  of survival  [6,7]. Two
recent analyses have attempted to de~ne a GH cut-off
for normalization of risk. Wrightson et al [8] used a
regression logistic model to demonstrate increased
chances for good clinical outcome and survival if the
last known serum GH was below 2 lg/L rather than
above 10 lg/L. Similarly, Bates et al [6] found that a
mean serum GH in acromegalic patients of less than 2.5
lg/L reduced mortality to normal levels.
Although a basal serum GH below 2.5 lg/L in
acromegaly is clearly preferable to a serum GH below
10 lg/L, the lower value does not necessarily insure
against morbidity. In the study by Bates et al [6], there
was a 40% increase in mortality over normal in sub-
jects with basal GH below 2.5 lg/L. Although this dif-
ference did not reach statistical signi~cance, this likely
was a result of the relatively small number of subjects.
It is probable that increased mortality would be dem-
onstrated at this lower GH level if more subjects had
been studied.
The  poor reliability of an average  GH below 2.5
lg/L to predict relative protection in individual
acromegalic patients is demonstrated in the 24-h GH
pro~les in Figure 1. The pro~le in the upper panel was
from a 40 year old man with newly-diagnosed and un-
treated gigantism. Despite the fact that his average
daily plasma GH was 1.6 lg/L and all of his GH concen-
trations were below 2.5 lg/L, plasma IGF-I was twice
the upper limit of normal. He had severe symptoms of
active GH hypersecretion with hyperhidrosis, head-
ache and progressive acral and mandibular enlarge-
ment. In contrast, the subject in lower panel was a
healthy young man. His mean daily GH was 1.7 lg/L
and serum IGF-I was within the normal range. Their
pro~les differ dramatically in that plasma GH concen-
trations in the normal subject were frequently below
0.2 lg/L. This suggests that simply lowering the mean
GH without restoring the pattern of GH to normal,
which includes periods of very low GH concentrations,
may not be adequate.
This case illustrates the dif~culty in de~ning an ab-
solute serum GH that is safe in all patients. Although
the epidemiological studies have suggested that a GH
below 2.5 lg/L is adequate, this clearly was not the
case for this patient. Perhaps this is because a serum
GH concentration of less than 2.5 lg/L does not indi-
cate restoration of normal pulsatile GH secretion. Until
recently, serum GH concentration was measured by
RIA using methods having a minimal detection limit of
0.3–0.5 lg/L. In contrast, newer immunochemilumino-
metric (ICMA) GH assays have minimum detection
limits below 0.01 lg/L. Prior to the ICMA assays, in-
terpulse GH concentrations were thought to be near
the lower detection limit of the RIA. Repeat analysis
of these same samples using ICMA has demonstrated
that interpulse GH concentrations are actually much
lower and well below the detection limit of any GH
RIA [9]. In normal young adults a random serum GH
measurement during the day greater than 2 lg/L is
infrequent whereas GH concentrations less than 0.5
lg/L occur approximately 50% of the time [10]. The
parameters of GH secretion and exposure leading to
acromegaly in the face of a normal mean daily serum
GH are yet to de~ned.
There are similar quali~cations regarding dynamic
testing of the GH axis. Instead of repeated blood sam-
pling to establish a reliable daily  mean  serum  GH,
some groups have used suppression of serum GH dur-
ing an oral glucose tolerance test to de~ne normal GH
secretion. Jenkins et al [5] found a high correlation
between  mean GH following oral glucose and basal
serum GH. Prior to the availability of supersensitive
GH ICMA, cure was assumed if serum GH fell below 2
lg/L following oral glucose(11). As with basal inter-
pulse GH measurements, the more sensitive GH as-
says showed that normal men and women suppress to
below 0.03 and 0.25 pg/ml respectively [12]. Therefore,
Fig. 1. 24 hour GH pro~les of a patient with active
acromegaly (top panel) and of a normal young man (lower
panel). Mean plasma GH was 1.6 lg/L in the patient with
acromegaly and 1.7 lg/L in the normal subject.
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data reporting “cure” based on GH suppression below
2 lg/L are suspect.
A better measure of the level of GH hypersecretion
is serum IGF-I. In contrast to the pulsatile release of
GH, serum IGF-I concentration is quite stable over the
day and correlates with mean daily GH concentration
in acromegalic subjects [13]. It is elevated even in pa-
tients with minimally active disease and “normal” se-
rum GH concentrations [14,15]. Of interest, we ob-
served that plasma GH was below 1.5 lg/L in nearly
90% of cases when IGF-I values were normal [16]. In
contrast, over 60% of GH concentrations below 1.5
lg/L were accompanied by an elevated IGF-I.
Although GH has some metabolic and endocrine ac-
tions that are independent of IGF-I, most of the clinical
manifestations of acromegaly are mediated through
IGF-I [17]. Moreover, serum IGF-I is a surrogate for
GH  secretion  and this single  test  readily separates
acromegalic from normal patients [11]. Therefore nor-
malization of IGF-I should be the goal of our therapies.
As of yet, there are no mortality data in acromegaly
strati~ed by serum IGF-I levels. However, it is likely
that the IGF-I concentrations are more informative
than mean GH concentration. In practice, most endo-
crinologists measure both parameters but tend to
make treatment decisions based on the degree of ele-
vation of serum IGF-I and the patients signs and
symptoms.
Pituitary Irradiation Ef~cacy
Technical aspects of pituitary irradiation will not be
discussed in this paper. For information on methods of
conventional pituitary irradiation, the interested
reader is directed to several excellent reviews [18,19].
There is little doubt that external beam radiation is
effective in lowering serum GH. Estimates for mean
GH decline over time are plotted in Figure 2. From
this graph, it is clear that there is a more rapid fall in
GH during the ~rst two years and the rate of fall sub-
sequently slows. The few data available for follow-up
for 10 years or greater has suggested that GH either
continues to decline, albeit slowly [20], or else reaches
a plateau at approximately 20% of the starting value
[21,22]. As has been the case with pituitary surgery,
criteria for successful pituitary irradiation have
evolved over time. Early studies using the liberal cri-
teria for “cure” of a GH less than 10 lg/L reported that
irradiation cured acromegaly in over 70% of patients
within 3 years [23]. A more recent study found that
77% of patients achieved a serum GH below 10 lg/L
Fig. 2. Post-radiation dynamics of serum GH concentrations from ~ve separate studies. Authors and reference numbers are given in
the legend.
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after 2–10 years but only 55% achieved a GH below 5
lg/L during the same time interval [21].
Various parameters have been suggested to predict
which patients will respond to pituitary irradiation.
Werner et al observed that patients with initial hyper-
prolactinemia responded better than did normopro-
lactinemic patients [24]. This however, has not been the
case in three other studies [18,25,26]. Preoperative sur-
gery did not alter the rate in decline of GH [18,22] nor
was the response to therapy dependent on age or gen-
der [26].
As suggested by Figure 2, the major determinant
for normalization of serum GH is the pre-irradiation
GH level. Based on the rates of GH fall found in various
studies, if the starting GH is 10 lg/L, it will take be-
tween 1 and 4 years to achieve a serum GH of less than
5 lg/L. If the starting GH is 100 lg/L, this goal will not
be realized for 10–20 years, if ever.
Yet, as discussed above, achievement of a serum GH
of less than 5 lg/L does not indicate cure. Nor does
serum GH below this level necessarily protect the pa-
tient from the morbidities associated with persistent
GH hypersecretion. Improvements in clinical parame-
ters of acromegaly such as arthralgias, hyperhidrosis
and glucose metabolism do occur following irradiation,
however the bene~ts are frequently not realized until
many years following treatment. Failure of pituitary
irradiation to effect a timely normalization of GH is
exempli~ed by the progression of cardiovascular dis-
ease following radiation therapy [27]. In contrast,
abrupt decreases in serum GH following pituitary apo-
plexy [28] or during octreotide treatment [29] have
been reported to arrest or improve cardiac abnormali-
ties. It is of interest to note that MacSweeney et al [30]
concluded that heel pad thickness was an insensitive
measure of biochemical “cure” after treatment with
yttrium-90 implantation. Yet, soft tissue thickness is
normal in acromegalics with inactive disease [31] and
soft tissue swelling decreases in patients treated with
octreotide who have normal serum IGF-I levels [32].
Cure in the yttrium-90 treated patients was de~ned as
a GH below 5 lg/L and these patients undoubtedly had
elevated serum IGF-I.
Although the effects of pituitary irradiation on se-
rum GH are well documented, the effects of this treat-
ment on IGF-I are not as well studied. Ciccarelli et al
[33] reported that pituitary irradiation normalized se-
rum IGF-I in 13/19 patients within 2–4 years of treat-
ment. Another study found normal or low IGF-I in
23/40 irradiated patients 3–12 years post irradiation
[34]. However, the validity of the IGF-I assays in these
reports is in  question.  In the  former study, normal
serum IGF-I was associated with frankly elevated
mean daily serum GH. In the latter report, a third of
patients with reportedly normal IGF-I had clinically
active acromegaly.
In contrast to these two studies, we [16] and others
[35] have recently reported on the ineffectiveness of
pituitary irradiation to normalize serum IGF-I. Data
from our study are presented in Figure 3. Of 38 pa-
tients followed for a maximum of 10 years, only two
patients receiving pituitary irradiation had a serum
IGF-I that was persistently within the age-and gen-
der-adjusted normal range. In contrast, serum GH rap-
idly declined following irradiation and 65% of the pa-
tients had a random GH of less than 5 lg/L within 5 yr.
Consistent with our results, Thalassinos et al [35] also
found that pituitary irradiation seldom resulted in
“safe” GH levels. In that study, serum GH fell below 2.5
lg/L in only 20% of their patients by 10 yr. Of a total of
21 patients who were followed for at least 10 year,
serum  IGF-I  data was  available on 14 subjects. Of
these, only 4 had normal IGF-I levels. It was not stated
whether their IGF-I normal ranges were corrected for
age and gender so that is conceivable that the number
of patients with a truly normal serum IGF-I was even
Fig. 3. Preoperative, postoperative and post-irradiation GH
and IGF-I values in 38 patients with acromegaly who were
treated with pituitary irradiation. Many values were obtained
while the patients were treated with medications (bro-
mocriptine or octreotide, open circles). Off medication values
are shown by the closed circles. Plasma IGF-I is expressed as a
percent of the age-and gender-speci~c upper limit of normal.
(From Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, DeMott
Friberg R, Chandler WF, et al. Pituitary irradiation is ineffec-
tive in normalizing plasma insulin-like growth factor I in pa-
tients with acromegaly. J Clin Endocrinol Metab
1997;82:3187–3191. © The Endocrine Society)
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lower. Subsequent to the publication by Barkan et al
[16] on the poor ef~cacy of pituitary irradiation to nor-
malize serum IGF-I in acromegaly, a preliminary re-
port claimed a 44% serum IGF-I normalization rate
with conventional therapy [36]. Further investigation
into this question is needed.
In summary, it can be safely concluded that pitui-
tary radiation rapidly lowers GH. Yet, GH secretion is
infrequently brought down to a level that results in
normalization of serum IGF-I, even after 10 years of
follow-up. This persistently elevated IGF-I is likely to
put irradiated patients at risk for further morbidity
associated with acromegaly. Whether other modalities
of radiotherapy will be found to be more effective is
unknown. Proton beam does not appear to have any
advantage over conventional external beam irradiation
and it may have more adverse effects [37]. Whether
gamma-knife radiation is more successful remains to be
seen. An early study on gamma-knife radiation in 21
patients with GH-secreting macroadenomas reported a
more rapid decline in GH with this therapy than is seen
with conventional irradiation [38]. Plasma GH concen-
trations fell below 2 lg/L in 5/21 of the patients who
underwent radiosurgery, however few IGF-I data
were given. Preliminary data demonstrating 20% nor-
malization of IGF-I by 6 years after gamma-knife
treatment is encouraging [39].
This high failure rate of conventional pituitary irra-
diation is not unexpected. The experience with this
therapy for the treatment of other types of pituitary
tumors would predict this. In the case of adult Cush-
ing’s disease, irradiation as a primary therapy results
in long term cure in at best 50–60% of patients [40,41],
although irradiation as a secondary treatment appears
to be ef~cacious [42]. Similar to the decline in GH in
acromegaly, irradiation of prolactinomas results in an
impressive initial fall in prolactin yet only 50% of pa-
tients achieved a normal prolactin after a mean follow-
up of 8.5 yr [43].
Although pituitary irradiation is not very effective
in normalizing  serum IGF-I it might play a role in
preventing further growth or in shrinking GH secret-
ing adenomas. Early studies observed a reduction in
fossa size by lateral skull ~lm or improvement in vis-
ual-~eld defects [25]. In addition, irradiation increases
recurrence-free rates post resection of large macroade-
nomas [19]. Eastman et al [18] reported that none of
their 86 patients had clinical symptoms that would sug-
gest progression of tumor size and, in a review of the
literature, they found evidence for tumor progression
in only 3/1027 acromegalic patients treated with radio-
therapy. Similarly, Tsang et al [44] reported that follow-
up computer tomography or magnetic imaging scans
indicated a 96% progression-free rate at 10 years in a
group of 145 patients with secretory pituitary tumors.
Of this group, 1/3 were acromegalics. Unfortunately,
the authors gave no further information on change in
tumor size or concomitant medical treatments. More
conclusive radiologic evidence for the bene~t of pitui-
tary irradiation in acromegaly was provided by Cic-
carelli et al [33]. They found that 3/19 GH secreting
tumors completely disappeared after 6 months and an-
other 4/19 decreased 20–55% in size within 36 months
of treatment.
Side Effects
In general, external beam pituitary irradiation is well
tolerated. The major risks are the development of hy-
popituitarism, visual loss or brain damage. Hypopitui-
tarism is common, and after exclusion of patients with
pre-irradiation hormonal de~ciency, the incidence of
secondary gonadal, adrenal or thyroid de~ciencies is as
high as  50, 37  and 37% respectively in acromegalic
patients [45,46]. The risk of hypopituitarism is dose
dependent and Littley et al [47] have suggested that 20
Gy and the standard dose of 50 Gy are equally effective
in suppressing serum GH. Others (48), however have
reported  less  ef~cacy  in decreasing  GH with lower
doses and hypopituitarism can occur even after treat-
ment with 20 Gy [49].
Visual loss is a rare side effect of conventional pitui-
tary radiation. It is estimated that the risk for this
complication in acromegalic patients is approximately
2% [18]. This number is probably an overestimation as
it includes patients who received dose fractions or total
irradiation in excess of current recommendation. How-
ever, visual loss due to radiation damage can occur
even when “safe” doses of are administered [50]. If the
total dose is limited to 45 Gy and the daily dose does
not exceed 2 Gy, it is likely that the risk of radiation
damage to the optic nerve or chiasm will be much lower
than the 2% estimate [23].
Potential brain damage resulting from pituitary ir-
radiation has been extensively reviewed by several
authors [18,51,52]. A variety of anatomical changes,
including cerebral atrophy, hypothalamic gliosis, tem-
poral lobe changes, and radiation necrosis have been
described. Cases of Kluver-Bucy syndrome [53] and
necrotizing brainstem leukoencephalopathy [54] fol-
lowing pituitary irradiation have occurred. al-Mefty et
al [51]. observed that abnormalities of brain paren-
chyma were present in 30% of patients with pituitary
tumors at a mean follow-up of 8 years. The clinical
signi~cance of these changes was uncertain. Grattan-
Smith et al [52] described four cases of radiation ne-
crosis out of 11 patients with Cushing’s disease who
received pituitary  irradiation. None of the  11 acro-
megalics and 1 of 17 patients with chromophobe ade-
noma developed this complication. Brain necrosis,
however is a rare event. Pooling data from a large
number of studies Sheline et al [55] concluded that the
risk of this occurring is 0.04–0.4%, depending on the
radiation dose and method of delivery.
The risk  of  development  of second brain tumors
following pituitary irradiation is uncertain. A retro-
spective analysis by Bliss et al [56] found only one
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malignant brain tumor in 296 patients irradiated for
pituitary adenoma in Edinburgh between 1962 and
1990 and a compilation of data from 37 studies that
included 1027 acromegalic patients found only two
cases of a secondary brain malignancy resulting from
the irradiation [18]. Jones [56a] similarly observed that
secondary brain tumors were rare in a series of 332
consecutive cases of pituitary adenoma irradiated. He
cautioned that few of the previous reports warning
against this potential side effect had   adequately
de~ned denominator groups and therefore could not
de~ne relative risk.
Several recent studies, however suggest that the
risk of secondary malignancy may be greater than that
reported earlier. Tsang et al [57], found 4 cases of
glioma in 305 patients with pituitary adenoma treated
with pituitary irradiation the tumors developed with a
latency of 8–15 yr. The patients had a relative risk of
malignant brain tumor of 16 times greater than the
general population and the cumulative actuarial risk of
secondary glioma was 2.7% at 15 yr post pituitary irra-
diation. Similarly, Brada et al [57a] concluded that the
relative risk for development of a second brain tumor
compared with the incidence in the normal population
was approximately 9. Simmons and Laws [58] recently
reported the diagnosis of gliomas in two patients with
acromegaly who had received pituitary irradiation.
They reviewed the literature and concluded that con-
ventional pituitary radiotherapy clearly increased the
risk for development of aggressive gliomas. Moreover,
they noted that a large proportion of these secondary
gliomas were associated with GH-secreting pituitary
adenomas. Although glioma appear to be the most fre-
quent secondary brain malignancy following pituitary
irradiation, development of meningioma [59] and astro-
cytoma [60] have also been reported.
An important question is whether pituitary irradia-
tion compromises intellectual function. It is the impres-
sion of may clinicians that this is the case. There are,
however no conclusive data on this question. Informa-
tion on intellectual development in children who have
received brain or pituitary irradiation is con_icting and
is confounded by the concomitant use of chemothera-
peutic agents in many of the children.
Conclusions
Until recently, pituitary irradiation was recommended
in acromegaly as a primary therapy or after failed at-
tempts at surgical cure. Although GH predictably falls
post-pituitary irradiation, several recent studies sug-
gest that this treatment infrequently results in nor-
malization of serum IGF-I. Hence, conventional irra-
diation is unlikely to protect patients from the
morbidities of acromegaly. It may therefore be neces-
sary to rethink the role of pituitary irradiation in this
disease. Since pituitary surgery has the potential to
rapidly cure some patients and, at the least, results in
a substantial fall in serum GH, most patients should
undergo  adenomectomy as  a ~rst step. Even if not
cured by surgery, the lower GH will allow subsequent
treatments to more likely normalize IGF-I. In most
patients who are not cured by surgery, the addition of
a long acting somatostatin agonist should be the next
step since octreotide normalizes serum IGF-I and re-
duces tumor size in approximately 50% and 35% of
patients respectively [61]. For those acromegalics who
are not cured by surgery but who have low enough GH
and IGF-I concentrations such that normalization can
be expected in a few years, treatment with either pi-
tuitary irradiation or a somatostatin analog should be
offered. The risks from pituitary irradiation are low,
however data on potential adverse effects on cognitive
function is lacking. Irradiated patients should receive
subsequent medical treatment with a long acting soma-
tostatin agonist until serum IGF-I normalizes. Pitui-
tary irradiation should also be considered if the post
surgical tumor residual grows in spite of medical treat-
ment and for those patients in whom somatostatin ana-
logs do not completely normalize serum IGF-I.
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